⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575807 | 0.78 | — | — | |
| SCHEMBL575446 | 0.78 | — | — | |
| SCHEMBL4811097 | 0.75 | — | — | |
| SCHEMBL6282193 | 0.73 | — | — | |
| SCHEMBL19348596 | 0.73 | — | — | |
| SCHEMBL19348592 | 0.73 | — | — | |
| SCHEMBL1009455 | 0.73 | — | — | |
| SCHEMBL29245174 | 0.73 | — | — | |
| SCHEMBL563900 | 0.73 | — | — | |
| SCHEMBL392532 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8067464-B2 | Compositions and methods using apocynin compounds and nitric oxide donors | NITROMED, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20100316622-A1 | DIAGNOSIS AND TREATMENT OF CARDIAC DISORDERS | UNIVERSITY OF MIAMI (US) | 2010-12-16 | — | — | US | disclosed |
| US-7838023-B2 | Furoxan compounds, compositions and methods of use | NITROMED, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | NITOMED, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253662-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | NITROMED, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| EP-1541590-A1 | Process for the oxidation of hydroxy compounds by means of nitroxy compounds | SCA Hygiene Products AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1541552-A1 | Process for the recovery of nitroxy compounds from organic solutions and oxidation process | SCA Hygiene Products AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1541566-A1 | Process for the separation of organic hydroxylamine and nitrosonium compounds and its use in the oxidation of hydroxy compounds | SCA Hygiene Products AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1541565-A1 | Process for the separation of organic nitrosonium and/or hydroxylamine compounds by means of cation exchange resins and recovery and oxidation processes based thereon | SCA Hygiene Products AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050121159-A1 | Process for the oxidation of hydroxy compounds by means of nitroxy compounds | SCA HYGIENE PRODUCTS AB (SE) | 2005-06-09 | — | — | US | disclosed |
| US-20050121160-A1 | Process for the separation of organic nitrosonium and/or hydroxylamine compounds by means of cation exchange resins and recovery and oxidation processes based thereon | SCA HYGIENE PRODUCTS AB (SE) | 2005-06-09 | — | — | US | disclosed |
| US-6617337-B1 | Administering to said patient a blood pressure lowering effective amount of a nitroxide selected from the group consisting of TEMPO, DOXYL and PROXYL. | GEORGETOWN UNIVERSITY | 2003-09-09 | — | — | US | disclosed |
| WO-2002026231-A1 | USE OF NITROXIDES FOR THE TREATMENT OF VASCULAR DISORDERS IN A DIABETIC MAMMAL | GEORGETOWN UNIVERSITY (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-1014980-A1 | USE OF NITROXIDES FOR THE TREATMENT OF ESSENTIAL HYPERTENSION | Georgetown University (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999013875-A1 | USE OF NITROXIDES FOR THE TREATMENT OF ESSENTIAL HYPERTENSION | GEORGETOWN UNIVERSITY MEDICAL CENTER (US) | 1999-03-25 | — | — | WO | disclosed |